Abstrait
Purpose of review
Liver transplantation is the gold standard for the treatment of end-stage liver disease. Cependant, Une pénurie d'organes donateurs, coût élevé, et les complications chirurgicales limitent l'utilisation de ce traitement. Thérapies cellulaires utilisant des hépatocytes, cellules souches hématopoïétiques, cellules mononucléaires de la moelle osseuse, et cellules souches mésenchymateuses (MSC) are being investigated as alternative treatments to liver transplantation. The purpose of this review is to describe studies using MSC transplantation for liver diseases based on the reported literature and to discuss prospective research designed to improve the efficacy of MSC therapy.
Recent findings
MSCs have several properties that show potential to regenerate injured tissues or organs, such as homing, transdifferentiation, immunosuppression, and cellular protective capacity. En plus, MSCs can be noninvasively isolated from various tissues and expandedex vivo in sufficient numbers for clinical evaluation.
Résumé
Actuellement, there is no approved MSC therapy for the treatment of liver disease. Cependant, MSC therapy is considered a promising alternative treatment for end-stage liver diseases and is reported to improve liver function safely with no side effects. Further robust preclinical and clinical studies will be needed to improve the therapeutic efficacy of MSC transplantation.
